To access this element change to forms mode OFF
Grant Award View - GA289061
Comparative Effectiveness of Ketamine and Esketamine in Treatment...
GA ID:
GA289061
Agency:
Department of Health and Aged Care
Approval Date:
9-Dec-2022
Publish Date:
20-Mar-2023
Category:
Medical Research
Grant Term:
1-Feb-2023 to 31-Jan-2027
Value (AUD):
$2,989,718.53
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 22/23 1.1 Health Policy Research and Analysis
Grant Program:
Medical Research Future Fund
Grant Activity:
Comparative Effectiveness of Ketamine and Esketamine in Treatment Resistant Depression
Purpose:
Ketamine is a highly effective new treatment for treatment-resistant depression. Two main forms of ketamine are available in Australia, a patented new drug, and a generic form of ketamine widely available at low cost. This will be the first study to directly compare these two forms of ketamine, in terms of effectiveness, acceptability, safety and cost effectiveness.
GO ID:
GO Title:
MRFF 2021 Clinical Trials Activity Grant Opportunity
Internal Reference ID:
2022/MRF2022782
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Kensington
Town/City:
Kensington
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, QLD
Postcode:
Multiple
Country:
AUSTRALIA